ESTRO meets Asia 2024 - Abstract Book

S226

Interdisciplinary – Mixed sites/palliation

ESTRO meets Asia 2024

We retrospectively analyzed cancer patients treated with SFRT using a commercially available brass GRID collimator (DotDecimal, Sanford FL) from January 2020 to December 2023 in the Department of Radiation Oncology, Cipto Mangunkusumo Hospital, Jakarta. Data were retrieved from the medical records.

Results:

A total of 33 patients with a median age of 47 (4-64) years old, were treated with GRID and all had palliative intent (n=33; 100%). The majority of patients were female (n=21; 63.63%), diagnosed with gynecologic and breast cancer (each n=7, 21.21%, respectively). Most patients received 15 Gy single dose GRID (n=32; 96.96%), as their first fraction (n=29; 87.87%), with two opposed beam arrangement techniques (n=21; 63.63%), and followed by either 2D/3D/IMRT (n=26; 78.78%) or SBRT (n=6; 18.18%). The clinical outcomes were PR (n=15; 45.45%), SD/PD (n=13; 39.39%), and CR (n=2; 6.06%). Pain palliation occurred in 92.3% (24/26) patients, mass reduction was observed in 84.61% (n=22/26) patients, and bleeding control was achieved in 81.81% (9/11) patients. No significant toxicities were reported.

Conclusion:

GRID SFRT is an effective treatment for bulky tumors and palliates symptoms with remarkable outcomes and considerable toxicity.

Keywords: bystander effects, spatially fractionated, GRID

References:

1. Zwicker RD, Meigooni A, Mohiuddin M. Radiobiological advantage of megavoltage grid therapy. Int J Radiat Oncol. 2001;51(3):401. 2. Asur R, Butterworth KT, Penagaricano JA, Prise KM, Griffin RJ. High dose bystander effects in spatially fractionated radiation therapy. Cancer Lett. 2015 Jan;356(1):52–7.